SCHEMBL4124838

SCHEMBL4124838

CC(C)(C)c1ccccc1NC(=O)Nc1ccc(OC(F)F)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.58
STING1 Q86WV6 1/20 0.57
P2RY1 P47900 9/20 0.57
MAPT P10636 6/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
LMNA P02545 2/20 0.54
HTT P42858 2/20 0.54
LPAR1 Q92633 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
P2RY14 Q15391 2/20 0.51
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
PKM P14618 1/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
MAPK1 P28482 1/20 0.49
ALDH1A1 P00352 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4106282 0.83 MAPT (0.61) STING1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL4124723 0.81 RAB9A (0.70) STING1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL4111928 0.80 MAPT (0.68) STING1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL4119167 0.80 KMT2A (0.63) STING1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL4118510 0.80 KMT2A (0.72) STING1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL4118526 0.80 MAPT (0.66) STING1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5852195 0.79 P2RY1 (0.70) IDO1STING1P2RY1MAPTMEN1
SCHEMBL4118509 0.78 HTT (0.55) STING1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL4105977 0.77 KMT2A (0.61) STING1P2RY1MAPTMEN1KMT2A
SCHEMBL4124133 0.76 MAPT (0.59) STING1MAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 IDO1 633/4885STING1 3480/4885P2RY1 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.